Fundraising Fox
Janux Therapeutics
La Jolla, US · Founded 2017 · 122 employees on LinkedIn · 3 known investors
Find your way into Janux Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Ryan Loggie to introduce you to David Bonita
You →Ryan · together at Orbimed →David
Ask Jamie Chen to introduce you to Tighe M. Reardon
You →Jamie · together at Arista MD →Tighe
Sign up to find every way you can get introduced to Janux Therapeutics
- Your email: who you already know at Janux Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Janux Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Janux Therapeutics is a clinical-stage biotech company developing precision-engineered immunotherapies for the treatment of cancer and autoimmune diseases. It uses its TRACTr, TRACIr, and ARM platforms to engineer drug candidates intended to direct the immune system against disease while limiting systemic safety issues.
Founders & leadership
Board
Investors · 3
How we know: Avalon BioVentures's portfolio page · Not right? Tell us
How we know: OrbiMed's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$192.4M disclosed across 3 rounds · 2020–2021
▶$125MraisedApr 2021 · 22 investors · BiotechnologyRule 506(b)
- Jay Lichter, Ph.D.Director
- Jake Simson, Ph.D.Director
- Stefan HellerDirector
- Peter Thompson, M.D.Director
- Vickie L. CappsDirector
- David Campbell, Ph.D.Executive Officer, Director
- Sheila GujrathiDirector
- Tighe ReardonExecutive Officer
- Offering amount
- $125M
- Amount sold
- $125M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$56MraisedMar 2021 · 7 investors · BiotechnologyRule 506(b)
- Jay Lichter, Ph.D.Director
- Jake Simson, Ph.D.Director
- Tighe ReardonExecutive Officer
- Stefan HellerDirector
- Peter Thompson, M.D.Director
- David Campbell, Ph.D.Executive Officer, Director
- Offering amount
- $56M
- Amount sold
- $56M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$11.4MraisedJul 2020 · 3 investors · BiotechnologyRule 506(b)
- Jay Lichter, Ph.D.Director
- Stefan HellerDirector
- Tighe ReardonExecutive Officer
- David Campbell, Ph.D.Executive Officer, Director
- Offering amount
- $15.9M
- Amount sold
- $11.4M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Janux Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Janux Therapeutics do?
- Janux Therapeutics is a clinical-stage biotech company developing precision-engineered immunotherapies for the treatment of cancer and autoimmune diseases. It uses its TRACTr, TRACIr, and ARM platforms to engineer drug candidates intended to direct the immune system against disease while limiting systemic safety issues.
- Who are Janux Therapeutics's investors?
- Janux Therapeutics's investors include Avalon BioVentures, OrbiMed, Samsara BioCapital.
- How much funding has Janux Therapeutics raised?
- Janux Therapeutics has disclosed $192.4M raised across 3 rounds.
- Where is Janux Therapeutics headquartered?
- Janux Therapeutics is headquartered in La Jolla, US.